Veracyte, a leading genomic diagnostics company, has joined forces with Illumina, a pioneer in DNA sequencing and array-based technologies, in a multi-year partnership aimed at developing molecular tests for decentralised in vitro diagnostic (IVD) applications. The collaboration focuses on leveraging Illumina’s NextSeq 550Dx instrument for the development of Veracyte’s Prosigna Breast Cancer Assay and Percepta Nasal Swab test.

Veracyte’s Prosigna Breast Cancer Assay is an established IVD test designed to assist healthcare professionals in making informed treatment decisions for individuals diagnosed with early-stage breast cancer. The test provides valuable genomic information that aids in tailoring treatment plans, contributing to more personalised and effective patient care.

The Percepta Nasal Swab test, on the other hand, is a non-invasive diagnostic tool intended to guide diagnosis and treatment decisions for individuals, particularly current and former smokers, with lung nodules that may be potentially cancerous. By offering a less-invasive method for assessing lung nodules, the Percepta Nasal Swab test addresses a critical need for accurate and timely lung cancer diagnostics.

The collaboration between Veracyte and Illumina holds significant implications for the global IVD market. The development of decentralised IVD tests aligns with a growing trend in healthcare towards point-of-care diagnostics and personalised medicine. Decentralised IVD tests enhance diagnostic accessibility, particularly in regions lacking centralised facilities, fostering early detection and treatment for improved patient outcomes. The integration of the Prosigna Breast Cancer Assay in decentralised settings facilitates personalised treatment strategies, while the innovative Percepta Nasal Swab test addresses the demand for less-invasive lung cancer diagnostics, aligning with global initiatives for early detection. The Veracyte and Illumina collaboration not only expands their market presence but also opens avenues for new IVD segments, potentially diversifying their molecular test offerings.

Veracyte and Illumina’s collaboration represents a significant stride in advancing decentralised molecular diagnostic tests. With a focus on improving accessibility, personalising treatment decisions, and innovating in lung cancer diagnostics, the partnership is poised to make a meaningful impact on the global IVD market. As these tests become more widely available, the potential benefits for patients, healthcare providers, and the diagnostic industry are substantial.